Integrated Diagnostics : Presentation for 9M2020 results
November 25, 2020 at 04:05 am EST
Share
9M2020 Results
Presentation
November 2020
Contents:
9M2020 Results
Covid-19Response Measures
Growth Strategies
Expanding Customer Reach
"Wayak" Investment
Al Borg Scan Updates
Nigeria Updates
Appendix
Results Snapshot
Group reports top- and bottom-line growth in 9M 2020, supported by a strong and broad-based
recovery in the third quarter of the year
EGP 1,670 mn
Revenue in 9M 2020
1% y-o-y
EGP 710 mn
EBITDA in 9M 2020
4% y-o-y / 43% margin
EGP 89
Average revenue per test in 9M 2020
▲25% y-o-y
18.8 mn
Tests completed in 9M 2020
▼19% y-o-y
EGP 830 mn
Gross Profit in 9M 2020
5% y-o-y / 50% margin
EGP 375 mn
Net Profit in 9M 2020
4% y-o-y / 22% margin
471
Operational branch labs in 9M 2020
▲19 branches vs FY2019
4.8 mn
Patients served in 9M 2020
▼14% y-o-y
9M 2019 figures included the impact of the 100 Million Healthy Lives campaign in Egypt. Excluding the campaign, the Group's consolidated revenue records a 4% year-on-yearrise.
Top-line growth was supported by the gradual lifting of restrictive measures, which saw the reopening of all branches during 3Q 2020, and IDH's ability to adapt its service offering to the changing dynamics.
IDH continues to ramp up its house call service in Egypt and now
offers Covid-19-related testing* in both Egypt and Jordan,
helping to drive volumes and top-line growth in both countries.
Patients served and test performed during 3Q 2020 recorded
impressive 43% and 46% quarter-on-quarter growth,
respectively.
*Covid-19-related tests include PCR and antibody testing as well as a bundle of inflammatory and clotting markers such as Complete Blood Picture, ESR, D-Dimer, Ferritin and CRP, among others.
3 INTEGRATED DIAGNOSTICS HOLDINGS
Quarterly Revenue Progression
IDH witnessed a sharp recovery starting in June 2020, which carried through into the third
quarter of the year
Revenue Change| Year-on-Year
23%
1%
-8%
-13%
1Q 2020
2Q 2020
3Q 2020
9M 2020
The year-to-date performance was supported by a strong third quarter, which saw the Group close up 23% versus 3Q 2019, one of its strongest year-on-yearrevenue growth rates for a single quarter.
IDH's house call services in Egypt continued to witness strong demand and in 3Q 2020 made up 21% of the country's revenues. Similarly, Covid-19-related testing, contributed to 20% of Egypt's revenue in 3Q2020 and to 32% of Jordan's top-line for the quarter.
4 INTEGRATED DIAGNOSTICS HOLDINGS
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
IDH - Integrated Diagnostics Holdings plc published this content on 25 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2020 09:04:08 UTC
Integrated Diagnostics Holdings PLC is a consumer healthcare company. The Company operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, histopathology, genetics, radiology and others. The Companyâs brands include Al Borg Scan, Al Mokhtabar, Ultralab, Biolab, Echo-Lab and others. It operates in approximately 552 branches. It offers more than 3,000 diagnostics tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy and substance abuse. Through Al Borg Scan, it offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT), electromyography (EMG), electrocardiogram (ECG), electroencephalogram (EEG), ultrasound, x-ray, mammograms and cath lab facilities.
INTEGRATED DIAGNOSTICS HOLDINGS PLC 
